OncRef

Clinical Trial: NCT02125461

A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

Status:

COMPLETED

Phase:

Phase 3

Lead Sponsor:AstraZeneca
Information Provided By:AstraZeneca
Last Update Posted:2023-10-10

Study Overview

Brief Summary

A Global Study to Assess the Effects of MEDI4736 following concurrent chemoradiation in Patients with Stage III Unresectable Non-Small Cell Lung Cancer.

Official Title

A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy (PACIFIC)

Conditions

Non-Small Cell Lung Cancer

Intervention / Treatment

  • Drug: MEDI4736
  • Other: PLACEBO

Other Study ID Numbers

  • D4191C00001
  • 2014-000336-42
  • 2014

Start Date (Actual)

2014-05-07

Primary Completion Date (Actual)

2017-02-13

Study Completion Date (Actual)

2023-08-24

Enrollment (Actual)

713

Study Type

Interventional

Phase

Phase 3